Regents Of The University Of California Rapt Therapeutics, Inc. Transaction History

Regents Of The University Of California

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	SELL	$16.28 - $24.6 $1.36 Million - $2.06 Million	-83,537 Reduced 70.52%	34,926 $691,000
Q3 2022 Nov 02, 2022	SELL	$17.96 - $30.46 $5.84 Million - $9.9 Million	-325,156 Reduced 73.3%	118,463 $2.85 Million
Q4 2021 Jan 24, 2022	SELL	$29.5 - $39.5 $4.87 Million - $6.52 Million	-165,044 Reduced 27.12%	443,619 $16.3 Million
Q3 2021 Oct 20, 2021	SELL	$29.86 - $39.47 $5.19 Million - $6.87 Million	-173,930 Reduced 22.22%	608,663 $18.9 Million
Q2 2021 Jul 27, 2021	SELL	$17.99 - $40.02 $3.91 Million - $8.7 Million	-217,407 Reduced 21.74%	782,593 $24.9 Million
Q1 2021 Apr 20, 2021	SELL	$16.0 - $24.46 $1.96 Million - $2.99 Million	-122,237 Reduced 10.89%	1,000,000 $22.2 Million
Q4 2020 Jan 21, 2021	SELL	$15.89 - $40.87 $4.11 Million - $10.6 Million	-258,467 Reduced 18.72%	1,122,237 $22.2 Million
Q3 2020 Oct 21, 2020	SELL	$21.6 - $37.5 $4.14 Million - $7.18 Million	-191,533 Reduced 12.18%	1,380,704 $44.5 Million
Q2 2020 Jul 23, 2020	BUY	$14.16 - $32.85 $22.3 Million - $51.6 Million	1,572,237 New	1,572,237 $45.6 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $24.9M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.